Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

AT1R-AT2R-RXFP1 Functional Crosstalk in Myofibroblasts: Impact on the Therapeutic Targeting of Renal and Cardiac Fibrosis.

Chow BSM, Kocan M, Shen M, Wang Y, Han L, Chew JY, Wang C, Bosnyak S, Mirabito-Colafella KM, Barsha G, Wigg B, Johnstone EKM, Hossain MA, Pfleger KDG, Denton KM, Widdop RE, Summers RJ, Bathgate RAD, Hewitson TD, Samuel CS.

J Am Soc Nephrol. 2019 Sep 11. pii: ASN.2019060597. doi: 10.1681/ASN.2019060597. [Epub ahead of print]

PMID:
31511361
2.

Profiling histone modifications in the normal mouse kidney and after unilateral ureteric obstruction.

Hewitson TD, Holt SG, Samuel CS, Wigg B, Smith ER.

Am J Physiol Renal Physiol. 2019 Sep 1;317(3):F606-F615. doi: 10.1152/ajprenal.00262.2019. Epub 2019 Jul 3.

PMID:
31268352
3.

The Use of Live Cell Imaging and Automated Image Analysis to Assist With Determining Optimal Parameters for Angiogenic Assay in vitro.

Huuskes BM, DeBuque RJ, Kerr PG, Samuel CS, Ricardo SD.

Front Cell Dev Biol. 2019 Apr 10;7:45. doi: 10.3389/fcell.2019.00045. eCollection 2019.

4.

Serelaxin enhances the therapeutic effects of human amnion epithelial cell-derived exosomes in experimental models of lung disease.

Royce SG, Patel KP, Mao W, Zhu D, Lim R, Samuel CS.

Br J Pharmacol. 2019 Jul;176(13):2195-2208. doi: 10.1111/bph.14666. Epub 2019 May 7.

PMID:
30883698
5.

Relaxin and fibrosis: Emerging targets, challenges, and future directions.

Kanai AJ, Konieczko EM, Bennett RG, Samuel CS, Royce SG.

Mol Cell Endocrinol. 2019 May 1;487:66-74. doi: 10.1016/j.mce.2019.02.005. Epub 2019 Feb 14. Review.

PMID:
30772373
6.

iPSC- and mesenchymoangioblast-derived mesenchymal stem cells provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid.

Royce SG, Mao W, Lim R, Kelly K, Samuel CS.

FASEB J. 2019 May;33(5):6402-6411. doi: 10.1096/fj.201802307R. Epub 2019 Feb 15.

PMID:
30768365
7.

Atypical cannabinoid ligands O-1602 and O-1918 administered chronically in diet-induced obesity.

Simcocks AC, Jenkin KA, O'Keefe L, Samuel CS, Mathai ML, McAinch AJ, Hryciw DH.

Endocr Connect. 2019 Mar 1;8(3):203-216. doi: 10.1530/EC-18-0535.

8.

Relaxin and extracellular matrix remodeling: Mechanisms and signaling pathways.

Ng HH, Shen M, Samuel CS, Schlossmann J, Bennett RG.

Mol Cell Endocrinol. 2019 May 1;487:59-65. doi: 10.1016/j.mce.2019.01.015. Epub 2019 Jan 17. Review.

PMID:
30660699
9.

Understanding relaxin signalling at the cellular level.

Valkovic AL, Bathgate RA, Samuel CS, Kocan M.

Mol Cell Endocrinol. 2019 May 1;487:24-33. doi: 10.1016/j.mce.2018.12.017. Epub 2018 Dec 25. Review.

PMID:
30592984
10.

Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.

Krishnan SM, Ling YH, Huuskes BM, Ferens DM, Saini N, Chan CT, Diep H, Kett MM, Samuel CS, Kemp-Harper BK, Robertson AAB, Cooper MA, Peter K, Latz E, Mansell AS, Sobey CG, Drummond GR, Vinh A.

Cardiovasc Res. 2019 Mar 15;115(4):776-787. doi: 10.1093/cvr/cvy252.

11.

The therapeutic effect of mesenchymal stem cells on pulmonary myeloid cells following neonatal hyperoxic lung injury in mice.

Al-Rubaie A, Wise AF, Sozo F, De Matteo R, Samuel CS, Harding R, Ricardo SD.

Respir Res. 2018 Jun 8;19(1):114. doi: 10.1186/s12931-018-0816-x.

12.

Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction.

McDonald H, Peart J, Kurniawan N, Galloway G, Royce S, Samuel CS, Chen C.

Physiol Rep. 2018 May;6(9):e13699. doi: 10.14814/phy2.13699.

13.

Serelaxin as a novel therapeutic opposing fibrosis and contraction in lung diseases.

Lam M, Royce SG, Samuel CS, Bourke JE.

Pharmacol Ther. 2018 Jul;187:61-70. doi: 10.1016/j.pharmthera.2018.02.004. Epub 2018 Feb 12. Review.

PMID:
29447958
14.

Endothelial Progenitor Cells and Vascular Health in Dialysis Patients.

Huuskes BM, DeBuque RJ, Polkinghorne KR, Samuel CS, Kerr PG, Ricardo SD.

Kidney Int Rep. 2017 Sep 18;3(1):205-211. doi: 10.1016/j.ekir.2017.09.004. eCollection 2018 Jan. No abstract available.

15.

Editorial: Novel Therapeutic Targets and Emerging Treatments for Fibrosis.

Samuel CS, Hewitson TD.

Front Pharmacol. 2017 Nov 14;8:824. doi: 10.3389/fphar.2017.00824. eCollection 2017. No abstract available.

16.

Relaxin contributes to the regulation of arterial pressure in adult female mice.

Mirabito Colafella KM, Samuel CS, Denton KM.

Clin Sci (Lond). 2017 Nov 28;131(23):2795-2805. doi: 10.1042/CS20171225. Print 2017 Dec 1.

PMID:
29101299
17.

Anti-fibrotic Potential of AT2 Receptor Agonists.

Wang Y, Del Borgo M, Lee HW, Baraldi D, Hirmiz B, Gaspari TA, Denton KM, Aguilar MI, Samuel CS, Widdop RE.

Front Pharmacol. 2017 Aug 31;8:564. doi: 10.3389/fphar.2017.00564. eCollection 2017. Review.

18.

Intranasal administration of mesenchymoangioblast-derived mesenchymal stem cells abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease.

Royce SG, Rele S, Broughton BRS, Kelly K, Samuel CS.

FASEB J. 2017 Sep;31(9):4168-4178. doi: 10.1096/fj.201700178R. Epub 2017 Jun 16.

PMID:
28626025
19.

Epigenetic Modifications to H3K9 in Renal Tubulointerstitial Cells after Unilateral Ureteric Obstruction and TGF-β1 Stimulation.

Hewitson TD, Holt SG, Tan SJ, Wigg B, Samuel CS, Smith ER.

Front Pharmacol. 2017 May 29;8:307. doi: 10.3389/fphar.2017.00307. eCollection 2017.

20.

ML290 is a biased allosteric agonist at the relaxin receptor RXFP1.

Kocan M, Sarwar M, Ang SY, Xiao J, Marugan JJ, Hossain MA, Wang C, Hutchinson DS, Samuel CS, Agoulnik AI, Bathgate RAD, Summers RJ.

Sci Rep. 2017 Jun 7;7(1):2968. doi: 10.1038/s41598-017-02916-5.

21.

Inhibition of the KCa3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model.

Organ L, Bacci B, Koumoundouros E, Kimpton WG, Samuel CS, Nowell CJ, Bradding P, Roach KM, Westall G, Jaffar J, Snibson KJ.

Am J Respir Cell Mol Biol. 2017 Apr;56(4):539-550. doi: 10.1165/rcmb.2016-0092OC.

PMID:
28060543
22.

Anakinra reduces blood pressure and renal fibrosis in one kidney/DOCA/salt-induced hypertension.

Ling YH, Krishnan SM, Chan CT, Diep H, Ferens D, Chin-Dusting J, Kemp-Harper BK, Samuel CS, Hewitson TD, Latz E, Mansell A, Sobey CG, Drummond GR.

Pharmacol Res. 2017 Feb;116:77-86. doi: 10.1016/j.phrs.2016.12.015. Epub 2016 Dec 13.

23.

Promise and Limitations of Relaxin-based Therapies in Chronic Fibrotic Lung Diseases.

Royce SG, Bathgate RA, Samuel CS.

Am J Respir Crit Care Med. 2016 Dec 1;194(11):1434-1435. No abstract available.

PMID:
27905854
24.

Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-Mediated Airway Relaxation.

Lam M, Royce SG, Donovan C, Jelinic M, Parry LJ, Samuel CS, Bourke JE.

Front Pharmacol. 2016 Oct 27;7:406. eCollection 2016.

25.

Serelaxin improves the therapeutic efficacy of RXFP1-expressing human amnion epithelial cells in experimental allergic airway disease.

Royce SG, Tominaga AM, Shen M, Patel KP, Huuskes BM, Lim R, Ricardo SD, Samuel CS.

Clin Sci (Lond). 2016 Dec 1;130(23):2151-2165. Epub 2016 Sep 19.

PMID:
27647937
26.

Estrogens do not protect, but androgens exacerbate, collagen accumulation in the female mouse kidney after ureteric obstruction.

Hewitson TD, Boon WC, Simpson ER, Smith ER, Samuel CS.

Life Sci. 2016 Aug 1;158:130-6. doi: 10.1016/j.lfs.2016.06.022. Epub 2016 Jun 29.

PMID:
27373424
27.

Anti-fibrotic actions of relaxin.

Samuel CS, Royce SG, Hewitson TD, Denton KM, Cooney TE, Bennett RG.

Br J Pharmacol. 2017 May;174(10):962-976. doi: 10.1111/bph.13529. Epub 2016 Jul 7. Review. Erratum in: Br J Pharmacol. 2017 Dec;174(24):4836.

28.

A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1.

Hossain MA, Kocan M, Yao ST, Royce SG, Nair VB, Siwek C, Patil NA, Harrison IP, Rosengren KJ, Selemidis S, Summers RJ, Wade JD, Bathgate RAD, Samuel CS.

Chem Sci. 2016 Jun 1;7(6):3805-3819. doi: 10.1039/c5sc04754d. Epub 2016 Feb 26.

29.

The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.

Wang C, Kemp-Harper BK, Kocan M, Ang SY, Hewitson TD, Samuel CS.

Front Pharmacol. 2016 Mar 31;7:91. doi: 10.3389/fphar.2016.00091. eCollection 2016.

30.

Combining an epithelial repair factor and anti-fibrotic with a corticosteroid offers optimal treatment for allergic airways disease.

Patel KP, Giraud AS, Samuel CS, Royce SG.

Br J Pharmacol. 2016 Jun;173(12):2016-29. doi: 10.1111/bph.13494. Epub 2016 May 5.

31.

Antifibrotic Actions of Serelaxin - New Roles for an Old Player.

Samuel CS, Summers RJ, Hewitson TD.

Trends Pharmacol Sci. 2016 Jun;37(6):485-497. doi: 10.1016/j.tips.2016.02.007. Epub 2016 Mar 17. Review.

PMID:
26996448
32.

Qualitative and Quantitative Analysis of Histone Deacetylases in Kidney Tissue Sections.

Ververis K, Marzully S, Samuel CS, Hewitson TD, Karagiannis TC.

Methods Mol Biol. 2016;1397:279-289. doi: 10.1007/978-1-4939-3353-2_19.

PMID:
26676140
33.

Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells.

Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ.

Br J Pharmacol. 2016 Feb;173(3):484-96. doi: 10.1111/bph.13371. Epub 2016 Jan 15.

34.

Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease.

Royce SG, Shen M, Patel KP, Huuskes BM, Ricardo SD, Samuel CS.

Stem Cell Res. 2015 Nov;15(3):495-505. doi: 10.1016/j.scr.2015.09.007. Epub 2015 Sep 25.

35.

Obligatory Role for B Cells in the Development of Angiotensin II-Dependent Hypertension.

Chan CT, Sobey CG, Lieu M, Ferens D, Kett MM, Diep H, Kim HA, Krishnan SM, Lewis CV, Salimova E, Tipping P, Vinh A, Samuel CS, Peter K, Guzik TJ, Kyaw TS, Toh BH, Bobik A, Drummond GR.

Hypertension. 2015 Nov;66(5):1023-33. doi: 10.1161/HYPERTENSIONAHA.115.05779. Epub 2015 Sep 8.

PMID:
26351030
36.

Electrophysiological, Electroanatomical, and Structural Remodeling of the Atria as Consequences of Sustained Obesity.

Mahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JP, Finnie JW, Samuel CS, Royce SG, Twomey DJ, Thanigaimani S, Kalman JM, Sanders P.

J Am Coll Cardiol. 2015 Jul 7;66(1):1-11. doi: 10.1016/j.jacc.2015.04.058.

37.

Inflammasome activity is essential for one kidney/deoxycorticosterone acetate/salt-induced hypertension in mice.

Krishnan SM, Dowling JK, Ling YH, Diep H, Chan CT, Ferens D, Kett MM, Pinar A, Samuel CS, Vinh A, Arumugam TV, Hewitson TD, Kemp-Harper BK, Robertson AA, Cooper MA, Latz E, Mansell A, Sobey CG, Drummond GR.

Br J Pharmacol. 2016 Feb;173(4):752-65. doi: 10.1111/bph.13230. Epub 2015 Jul 31.

38.

M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss, and elevated blood pressure.

Moore JP, Vinh A, Tuck KL, Sakkal S, Krishnan SM, Chan CT, Lieu M, Samuel CS, Diep H, Kemp-Harper BK, Tare M, Ricardo SD, Guzik TJ, Sobey CG, Drummond GR.

Am J Physiol Heart Circ Physiol. 2015 Sep;309(5):H906-17. doi: 10.1152/ajpheart.00821.2014. Epub 2015 Jun 12.

39.

Synthetic covalently linked dimeric form of H2 relaxin retains native RXFP1 activity and has improved in vitro serum stability.

Nair VB, Bathgate RA, Separovic F, Samuel CS, Hossain MA, Wade JD.

Biomed Res Int. 2015;2015:731852. doi: 10.1155/2015/731852. Epub 2015 Jan 22.

40.

NOX1 deficiency in apolipoprotein E-knockout mice is associated with elevated plasma lipids and enhanced atherosclerosis.

Sobey CG, Judkins CP, Rivera J, Lewis CV, Diep H, Lee HW, Kemp-Harper BK, Broughton BR, Selemidis S, Gaspari TA, Samuel CS, Drummond GR.

Free Radic Res. 2015 Feb;49(2):186-98. doi: 10.3109/10715762.2014.992893.

PMID:
25496431
41.

Cryotherapy for acute haemarthrosis in haemophilia--attempts to understand the 'ice age' practice.

Tilak M, Paul A, Samuel CS, David JA, Viswabandya A, Srivastava A.

Haemophilia. 2015 Jan;21(1):e103-5. doi: 10.1111/hae.12581. Epub 2014 Dec 4. No abstract available.

PMID:
25471230
42.

Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy.

Huuskes BM, Wise AF, Cox AJ, Lim EX, Payne NL, Kelly DJ, Samuel CS, Ricardo SD.

FASEB J. 2015 Feb;29(2):540-53. doi: 10.1096/fj.14-254789. Epub 2014 Nov 13.

PMID:
25395452
43.

Serelaxin-mediated signal transduction in human vascular cells: bell-shaped concentration-response curves reflect differential coupling to G proteins.

Sarwar M, Samuel CS, Bathgate RA, Stewart DR, Summers RJ.

Br J Pharmacol. 2015 Feb;172(4):1005-19. doi: 10.1111/bph.12964. Epub 2014 Dec 1.

44.

Characterization of a novel model incorporating airway epithelial damage and related fibrosis to the pathogenesis of asthma.

Royce SG, Patel KP, Samuel CS.

Lab Invest. 2014 Dec;94(12):1326-39. doi: 10.1038/labinvest.2014.119. Epub 2014 Sep 29.

45.

Qualitative and quantitative analysis of fibrosis in the kidney.

Hewitson TD, Smith ER, Samuel CS.

Nephrology (Carlton). 2014 Nov;19(11):721-6. doi: 10.1111/nep.12321.

PMID:
25196487
46.

Intranasally administered serelaxin abrogates airway remodelling and attenuates airway hyperresponsiveness in allergic airways disease.

Royce SG, Lim CX, Patel KP, Wang B, Samuel CS, Tang ML.

Clin Exp Allergy. 2014 Nov;44(11):1399-408. doi: 10.1111/cea.12391.

PMID:
25113628
47.

Low-dose maternal alcohol consumption: effects in the hearts of offspring in early life and adulthood.

Nguyen VB, Probyn ME, Campbell F, Yin KV, Samuel CS, Zimanyi MA, Bertram JF, Black MJ, Moritz KM.

Physiol Rep. 2014 Jul 30;2(7). pii: e12087. doi: 10.14814/phy2.12087. Print 2014 Jul 1.

48.

Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease.

Samuel CS, Bodaragama H, Chew JY, Widdop RE, Royce SG, Hewitson TD.

Hypertension. 2014 Aug;64(2):315-22. doi: 10.1161/HYPERTENSIONAHA.114.03594.

PMID:
24866131
49.

Human mesenchymal stem cells alter macrophage phenotype and promote regeneration via homing to the kidney following ischemia-reperfusion injury.

Wise AF, Williams TM, Kiewiet MB, Payne NL, Siatskas C, Samuel CS, Ricardo SD.

Am J Physiol Renal Physiol. 2014 May 15;306(10):F1222-35. doi: 10.1152/ajprenal.00675.2013. Epub 2014 Mar 12.

50.

Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis.

Royce SG, Moodley Y, Samuel CS.

Pharmacol Ther. 2014 Mar;141(3):250-60. doi: 10.1016/j.pharmthera.2013.10.008. Epub 2013 Oct 25. Review.

PMID:
24513131

Supplemental Content

Loading ...
Support Center